CORAL SPRINGS, Florida, February 5, 2013 /PRNewswire/ --
FinancialNewsMedia.com "Active Health Stocks to Watch" for today: Crown Marketing Pharmaceuticals (CWNM), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Rexahn Pharmaceuticals, Inc. (NYSE: RNN), Amarin Corporation (NASDAQ: AMRN).
Headline News Summary: Crown Marketing Pharmaceuticals (CWNM) announced today that Patents for its Controlled Drug Delivery Technology (CDDT) have been approved and registered in Norway. Crown is continuing to secure its worldwide patent rights as it pursues novel applications of its drug delivery technology. Crown's cost-effective application of controlled delivery technologies plays a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through its ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers. The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels. For more details regarding Crown's CDDT applications, go to http://crowncddt.com/technology/
Another major pharmaceutical company catching attention in the markets today was Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) as questions arose regarding the company's ability to convince the FDA to grant New Chemical Entity status to KERX's experimental iron-based phosphate binder Zerenex. Keryx intends to seek U.S. and European approval for Zerenex, which would be used to lower blood levels of phosphorous in patients undergoing kidney dialysis. Zerenex may have a commercial advantage over other so-called phosphate binders because its iron-based core appears to reduce the need for intravenous iron and expensive anemia-boosting drugs like Amgen Inc.'s (NASDAQ: AMGN) Epogen. Epogen is used to treat a lower than normal number of red blood cells (anemia) caused by chronic kidney disease in patients on dialysis to lessen the need for red blood cell transfusions.
In other patent related news, Amarin Corporation (NASDAQ: AMRN) announced recently that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/272,520 titled "Compositions and Methods for Lowering Triglycerides." This application includes claims intended to protect the proposed Vascepa (icosapent ethyl) indication based on Amarin's Phase 3 ANCHOR clinical trial results. Amarin is on track to file a Supplemental New Drug Application for the Vascepa ANCHOR indication with the U.S. Food and Drug Administration (FDA) by the end of February 2013, and expects an FDA action date on the application before the end of 2013. AMRN closed up ever so slightly yesterday at $8.52 per share on over 3.45Million shares. Rexahn Pharmaceuticals, Inc. (NYSE: RNN) closed up 12% on 6.76Million shares traded. RNN is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer and other unmet medical needs. Rexahn currently has three key oncology drug candidates in clinical stages, Archexin(R), RX-3117, and RX-5902 and a robust pipeline of preclinical compounds to treat multiple cancers. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visithttp://www.financialnewsmedia.com for more details.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
|SOURCE FN Media Group LLC|
Copyright©2012 PR Newswire.
All rights reserved